{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:58:51Z","timestamp":1792432731753,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omton.2024.200771","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:49:59Z","timestamp":1707281399000},"page":"200771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the ribosome to treat multiple myeloma"],"prefix":"10.1016","volume":"32","author":[{"given":"Kylee H.","family":"Maclachlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezia","family":"Gitareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9998-4975","authenticated-orcid":false,"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cuddihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleen","family":"Cullinane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Seng","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Brajanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Sanij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Poortinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200771_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2024.200771_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2024.200771_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the Proteasome Inhibitors: Lessons from\u00a0Multiple Myeloma and Mantle Cell Lymphoma","volume":"1233","author":"Gonzalez-Santamarta","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omton.2024.200771_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.omton.2024.200771_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2024.200771_bib6","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.3390\/cancers14215340","article-title":"Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200771_bib7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s12276-022-00884-z","article-title":"Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness","volume":"54","author":"Jung","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omton.2024.200771_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","article-title":"Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2024.200771_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2024.200771_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/biom12060802","article-title":"The Translational Regulation in mTOR Pathway","volume":"12","author":"Yang","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2024.200771_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00070-18","article-title":"Signaling Pathways Involved in the Regulation of mRNA Translation","volume":"38","author":"Roux","year":"2018","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2024.200771_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/2159-8290.CD-14-0673","article-title":"Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma","volume":"6","author":"Devlin","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2024.200771_bib13","doi-asserted-by":"crossref","first-page":"e105111","DOI":"10.15252\/embj.2020105111","article-title":"Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis","volume":"39","author":"Kusnadi","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2024.200771_bib14","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2016-05-718171","article-title":"Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population","volume":"129","author":"Hein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2024.200771_bib16","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","article-title":"CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition","volume":"20","author":"Lawrence","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2024.200771_bib17","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-16-0124","article-title":"The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer","volume":"22","author":"Rebello","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200771_bib18","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41467-020-16393-4","article-title":"CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer","volume":"11","author":"Sanij","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200771_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","article-title":"The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer","volume":"124","author":"Yan","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2024.200771_bib20","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-021-26640-x","article-title":"The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200771_bib21","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.18632\/oncotarget.4093","article-title":"rRNA synthesis inhibitor, CX-5461, activates ATM\/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis","volume":"6","author":"Negi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200771_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.14525","article-title":"RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma","volume":"177","author":"Lee","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2024.200771_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2024.200771_bib24","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/s41467-022-31199-2","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13","author":"Hilton","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200771_bib25","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1073\/pnas.1921649117","article-title":"The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning","volume":"117","author":"Bruno","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200771_bib26","doi-asserted-by":"crossref","first-page":"14432","DOI":"10.1038\/ncomms14432","article-title":"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours","volume":"8","author":"Xu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200771_bib27","doi-asserted-by":"crossref","first-page":"49800","DOI":"10.18632\/oncotarget.10452","article-title":"Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM\/ATR signaling","volume":"7","author":"Quin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200771_bib28","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200771_bib29","doi-asserted-by":"crossref","first-page":"eabb5953","DOI":"10.1126\/sciadv.abb5953","article-title":"Transcriptional suppression of ribosomal DNA with phase separation","volume":"6","author":"Ide","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2024.200771_bib30","doi-asserted-by":"crossref","first-page":"zcaa032","DOI":"10.1093\/narcan\/zcaa032","article-title":"The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability","volume":"2","author":"Mars","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omton.2024.200771_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc.2017.104","article-title":"Ribosome biogenesis in cancer: new players and therapeutic avenues","volume":"18","author":"Pelletier","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2024.200771_bib32","doi-asserted-by":"crossref","first-page":"13972","DOI":"10.1038\/s41598-022-17923-4","article-title":"CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response","volume":"12","author":"Snyers","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2024.200771_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3389\/fcell.2020.00568","article-title":"rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461","volume":"8","author":"Son","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2024.200771_bib34","doi-asserted-by":"crossref","first-page":"e65184","DOI":"10.7554\/eLife.65184","article-title":"Transcription-associated topoisomerase 2\u03b1 (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands","volume":"10","author":"Bossaert","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.omton.2024.200771_bib35","doi-asserted-by":"crossref","first-page":"e0127828","DOI":"10.1371\/journal.pone.0127828","article-title":"Whole Genome Sequence of Multiple Myeloma-Prone C57BL\/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types","volume":"10","author":"Amend","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200771_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2024.200771_bib37","doi-asserted-by":"crossref","first-page":"W304","DOI":"10.1093\/nar\/gkab359","article-title":"KEA3: improved kinase enrichment analysis via data integration","volume":"49","author":"Kuleshov","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2024.200771_bib38","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/bioinformatics\/btaa916","article-title":"Phosphomatics: interactive interrogation of substrate\u2013kinase networks in global phosphoproteomics datasets","volume":"37","author":"Leeming","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omton.2024.200771_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","article-title":"Overcoming proteasome inhibitor resistance in the immunotherapy era","volume":"44","author":"Pati\u00f1o-Escobar","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omton.2024.200771_bib40","doi-asserted-by":"crossref","first-page":"103246","DOI":"10.1016\/j.dnarep.2021.103246","article-title":"The FAcilitates Chromatin Transcription (FACT) complex: Its roles in DNA repair and implications for cancer therapy","volume":"109","author":"Bhakat","year":"2022","journal-title":"DNA Repair"},{"key":"10.1016\/j.omton.2024.200771_bib41","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1074\/jbc.M110.177394","article-title":"The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease","volume":"286","author":"Reijns","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omton.2024.200771_bib42","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1158\/0008-5472.CAN-07-1015","article-title":"Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway Activation","volume":"67","author":"Jacquemont","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200771_bib43","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fgene.2015.00098","article-title":"Regulation of the DNA damage response by ubiquitin conjugation","volume":"6","author":"Brinkmann","year":"2015","journal-title":"Front. Genet."},{"key":"10.1016\/j.omton.2024.200771_bib45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib46","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2022-166614","article-title":"V\u03ba\u2217MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma","volume":"140","author":"Maura","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.yexcr.2018.01.005","article-title":"Crucial role of HO-1\/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma","volume":"363","author":"Tang","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2024.200771_bib48","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/ncomms2599","article-title":"Topoisomerase II\u03b1 promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation","volume":"4","author":"Ray","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200771_bib49","doi-asserted-by":"crossref","first-page":"129016","DOI":"10.1016\/j.bmcl.2022.129016","article-title":"A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex)","volume":"77","author":"Xu","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.omton.2024.200771_bib50","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib51","doi-asserted-by":"crossref","first-page":"e73710","DOI":"10.1371\/journal.pone.0073710","article-title":"Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer","volume":"8","author":"Cron","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200771_bib52","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200771_bib53","doi-asserted-by":"crossref","first-page":"e08153","DOI":"10.7554\/eLife.08153","article-title":"Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits","volume":"4","author":"Acosta-Alvear","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.omton.2024.200771_bib54","doi-asserted-by":"crossref","first-page":"eaal2668","DOI":"10.1126\/scitranslmed.aal2668","article-title":"Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma","volume":"9","author":"Manier","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2024.200771_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","article-title":"Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma","volume":"15","author":"Li","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2024.200771_bib56","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3892\/ijo.2014.2774","article-title":"Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E","volume":"46","author":"Zismanov","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2024.200771_bib57","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-20-2246","article-title":"Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy","volume":"27","author":"Walker","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200771_bib58","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1093\/nar\/gkt171","article-title":"A rapid and sensitive assay for DNA-protein covalent complexes in living cells","volume":"41","author":"Kiianitsa","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2024.200771_bib59","doi-asserted-by":"crossref","first-page":"fcac305","DOI":"10.1093\/braincomms\/fcac305","article-title":"Phosphoproteomic dysregulation in Huntington's disease mice is rescued by environmental enrichment","volume":"4","author":"Mees","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.omton.2024.200771_bib60","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2024.200771_bib61","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T02:05:43Z","timestamp":1726884343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2950329924000134"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200771","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3582717\/v1","asserted-by":"object"}]},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the ribosome to treat multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"200771"}}